These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32310169)

  • 21. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
    Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
    Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
    Reger MA; Henderson ST; Hale C; Cholerton B; Baker LD; Watson GS; Hyde K; Chapman D; Craft S
    Neurobiol Aging; 2004 Mar; 25(3):311-4. PubMed ID: 15123336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypometabolism as a therapeutic target in Alzheimer's disease.
    Costantini LC; Barr LJ; Vogel JL; Henderson ST
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S16. PubMed ID: 19090989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
    Wilcock GK; Lilienfeld S; Gaens E
    BMJ; 2000 Dec; 321(7274):1445-9. PubMed ID: 11110737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
    Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
    Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.
    Rosenbloom M; Barclay TR; Kashyap B; Hage L; O'Keefe LR; Svitak A; Pyle M; Frey W; Hanson LR
    Drugs Aging; 2021 May; 38(5):407-415. PubMed ID: 33719017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
    Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
    N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease.
    Chamberlain S; Gabriel H; Strittmatter W; Didsbury J
    J Alzheimers Dis; 2020; 73(3):1085-1103. PubMed ID: 31884472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study.
    Ohnuma T; Toda A; Kimoto A; Takebayashi Y; Higashiyama R; Tagata Y; Ito M; Ota T; Shibata N; Arai H
    Clin Interv Aging; 2016; 11():29-36. PubMed ID: 26811674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
    Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
    Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Farlow MR; Cyrus PA
    Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
    Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
    Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease.
    Maher-Edwards G; Zvartau-Hind M; Hunter AJ; Gold M; Hopton G; Jacobs G; Davy M; Williams P
    Curr Alzheimer Res; 2010 Aug; 7(5):374-85. PubMed ID: 20043816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.